A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

doi:10.1158/1078-0432.CCR-23-3171

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2024

Embaby Alaa, Huijberts Sanne C F A, Wang Liqin, Leite de Oliveira Rodrigo, Rosing Hilde, Nuijen Bastiaan, Sanders Joyce, Hofland Ingrid, van Steenis Charlaine, Kluin Roelof J C, Lieftink Cor, Smith Christopher G, Blank Christian U, van Thienen Johannes V, Haanen John B A G, Steeghs Neeltje, Opdam Frans L, Beijnen Jos H, Huitema Alwin D R, Bernards Rene, Schellens Jan H M, Wilgenhof Sofie

Abstract excerpt

PURPOSE: The development of resistance limits the clinical benefit of BRAF and MEK inhibitors (BRAFi/MEKi) in BRAFV600-mutated melanoma. It has been shown that short-term treatment (14 days) with vorinostat was able to initiate apoptosis of resistant tumor cells. We aimed to assess the antitumor activity of sequential treatment with vorinostat following BRAFi/MEKi in patients with BRAFV600-mutated melanoma who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Histone Deacetylase Inhibitors

Share to Melanoma

Share to Proof of Concept Study

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Vorinostat

Source

Open in PubMed

Identifiers

PMID: 38739109
DOI: 10.1158/1078-0432.CCR-23-3171

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.PMID 38739109Read ↗

Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study.Semantic proximity Read ↗

Phase II trial of vorinostat in advanced melanoma.Semantic proximity Read ↗

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistanceSemantic proximity Read ↗

An overview of binimetinib for the treatment of melanoma.Semantic proximity Read ↗

MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study.Semantic proximity Read ↗

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.Semantic proximity Read ↗

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.Semantic proximity Read ↗

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.Semantic proximity Read ↗

Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant Melanoma.Semantic proximity Read ↗

Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma.Semantic proximity Read ↗

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.Semantic proximity Read ↗

MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS -, and NF1 -Mutant MelanomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.